Sharma A, Schwartz RA, et al.
Journal of the American Academy of Dermatology. Date of publication 2012 Dec 1;volume 67(6):1342-8.
1. J Am Acad Dermatol. 2012 Dec;67(6):1342-8. doi: 10.1016/j.jaad.2012.04.028. Epub
2012 Jun 8.
Stewart-Treves syndrome: pathogenesis and management.
Sharma A(1), Schwartz RA.
Author information:
(1)Dermatology and Pathology, New Jersey Medical School, Newark, New Jersey
07103-2714, USA.
Stewart-Treves syndrome is a malignancy that arises within chronic lymphedema.
Although classically described as a consequence of radical mastectomy, this
lymphangiosarcoma has been documented to occur in cases of congenital and other
causes of chronic secondary lymphedema. The development of this aggressive
lymphangiosarcoma at sites of chronic lymphedema renders it a possible model for
Kaposi sarcoma. Because of the increase in conservative treatment for breast
carcinoma and improvement of operative and radiation therapy techniques, the
prevalence of Stewart-Treves syndrome has decreased. Regardless, this malignancy
significantly worsens patients' outcomes and needs to be diagnosed and treated
early. Chemotherapy and radiation therapy have not improved survivorship
significantly. Early amputation or wide local excision offers the best chance for
long-term survival. Yet, overall prognosis remains dismal. Untreated patients
usually live 5 to 8 months after diagnosis.
Copyright © 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc.
All rights reserved.
DOI: 10.1016/j.jaad.2012.04.028
PMID: 22682884 [Indexed for MEDLINE]
Appears in following Topics: